LEGN
Legend Biotech Corporation
Price Chart
Latest Quote
$28.73
-0.64 (-2.20%)
Current Price
| Previous Close | $29.38 |
| Open | $29.25 |
| Day High | $29.98 |
| Day Low | $28.13 |
| Volume | 822,296 |
Stock Information
| Shares Outstanding | 193.44M |
| Total Debt | $389.30M |
| Cash Equivalents | $834.60M |
| Revenue | $1.14B |
| Net Income | $-250.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.56B |
| EPS (TTM) | $-1.38 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.01B |
| Sales | $1.14B |
| Income | $-250.10M |
| Book/sh | $5.21 |
| Cash/sh | $4.31 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 2.01 |
| Current Ratio | 2.13 |
| Debt/Eq | 40.23 |
Returns & Margins
| ROA | -5.24% |
| ROE | -25.19% |
| Gross Margin | 54.99% |
| Operating Margin | -16.32% |
| Profit Margin | -21.96% |
Ownership
| Insider Ownership | 1.26% |
| Institutional Ownership | 52.79% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 21.52 |
| P/S | 4.88 |
| P/B | 5.52 |
Analyst Data
| Recommendation | buy |
| Target Price | $57.59 |
Technical Indicators
| SMA20 | $31.95 |
| SMA50 | $28.40 |
| SMA200 | $25.60 |
| RSI | 35.02 |
| ATR | 2.2575 |
| Shares Float | 82.49M |
| Short Float | 17.10% |
| Short Ratio | 5.37 |
| Volatility | 0.35 |
| Rel Volume | 0.24 |
Performance History
| Week | -14.28% |
| Month | -2.69% |
| Quarter | +63.27% |
| 6 Months | +26.64% |
| YTD | +33.59% |
| Year | -16.22% |
| 3 Years | -60.23% |
| 5 Years | -25.86% |
| 10 Years | -22.34% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $28.74 | 822,344 |
| 2026-06-24 | $29.38 | 2,077,000 |
| 2026-06-23 | $29.30 | 2,087,400 |
| 2026-06-22 | $29.34 | 3,664,400 |
| 2026-06-18 | $27.93 | 13,608,400 |
| 2026-06-17 | $33.52 | 1,058,200 |
| 2026-06-16 | $33.38 | 2,005,500 |
| 2026-06-15 | $35.48 | 1,449,900 |
| 2026-06-12 | $35.87 | 1,700,300 |
| 2026-06-11 | $36.28 | 1,975,900 |
| 2026-06-10 | $34.86 | 1,910,000 |
| 2026-06-09 | $33.49 | 2,579,700 |
| 2026-06-08 | $31.52 | 3,203,500 |
| 2026-06-05 | $32.62 | 2,484,500 |
| 2026-06-04 | $34.20 | 3,415,200 |
| 2026-06-03 | $35.98 | 4,088,600 |
| 2026-06-02 | $36.28 | 14,632,600 |
| 2026-06-01 | $25.51 | 3,118,900 |
| 2026-05-29 | $27.16 | 2,451,900 |
| 2026-05-28 | $28.26 | 1,343,900 |
| 2026-05-27 | $28.50 | 1,437,400 |
| 2026-05-26 | $29.53 | 1,574,300 |
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
đ° Latest News
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress
Insider Monkey âĸ 2026-06-25T12:40:48Z
After Apogee, 3 More Biotech Buyout Targets Wall Street Canât Stop Watching
24/7 Wall St. âĸ 2026-06-24T11:55:10Z
Legend Biotech (LEGN) Reports a Complete Response in Five of Six Patients at Its Highest Dose
Insider Monkey âĸ 2026-06-22T14:14:26Z
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment
MT Newswires âĸ 2026-06-18T12:57:23ZImviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
Exec Edge âĸ 2026-06-11T19:56:49Z
Legend Biotech (LEGN) Is Up 26.2% After Early In Vivo CAR-T Success in B-Cell Lymphoma
Simply Wall St. âĸ 2026-06-04T13:12:18Z
Legend surges on early data for âin vivoâ lymphoma cell therapy
BioPharma Dive âĸ 2026-06-03T11:57:00Z
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results
Insider Monkey âĸ 2026-06-03T00:14:44Z
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
Investor's Business Daily âĸ 2026-06-02T20:30:11Z
Legend Stock Surges After Blood- Cancer Drug Shrinks Tumors in Study
The Wall Street Journal âĸ 2026-06-02T18:40:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $408,100,000 | $234,600,000 | $144,200,000 | $65,363,000 |
| Cost Of Revenue | $408,100,000 | $234,600,000 | $144,200,000 | $65,363,000 |
| Total Revenue | $1,028,900,000 | $627,300,000 | $285,100,000 | $117,005,000 |
| Operating Revenue | $1,028,600,000 | $621,000,000 | $285,000,000 | $116,677,000 |
| Expenses | ||||
| Interest Expense | $21,400,000 | $21,600,000 | $21,800,000 | $10,796,000 |
| Total Expenses | $1,165,400,000 | $936,800,000 | $813,200,000 | $572,625,000 |
| Other Income Expense | $-164,800,000 | $111,800,000 | $-24,800,000 | $12,510,000 |
| Other Non Operating Income Expenses | $4,000,000 | $2,500,000 | $3,400,000 | $-8,993,000 |
| Net Non Operating Interest Income Expense | $18,700,000 | $39,600,000 | $32,700,000 | $-2,614,000 |
| Interest Expense Non Operating | $21,400,000 | $21,600,000 | $21,800,000 | $10,796,000 |
| Operating Expense | $757,300,000 | $702,200,000 | $669,000,000 | $507,262,000 |
| Other Operating Expenses | $1,000,000 | $4,400,000 | $85,800,000 | $-2,434,000 |
| Selling And Marketing Expense | $205,800,000 | $147,500,000 | $94,200,000 | $93,417,000 |
| General And Administrative Expense | $135,800,000 | $136,800,000 | $106,800,000 | $80,631,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Net Interest Income | $18,700,000 | $39,600,000 | $32,700,000 | $-2,614,000 |
| Interest Income | $40,100,000 | $61,200,000 | $54,500,000 | $8,182,000 |
| Normalized Income | $-163,448,000 | $-263,347,000 | $-490,202,999 | $-463,336,370 |
| Net Income From Continuing And Discontinued Operation | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Total Operating Income As Reported | $-136,500,000 | $-309,500,000 | $-528,100,000 | - |
| Net Income Common Stockholders | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Net Income | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Net Income Including Noncontrolling Interests | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Net Income Continuous Operations | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Pretax Income | $-282,600,000 | $-158,100,000 | $-520,200,000 | $-445,724,000 |
| Interest Income Non Operating | $40,100,000 | $61,200,000 | $54,500,000 | $8,182,000 |
| Operating Income | $-136,500,000 | $-309,500,000 | $-528,100,000 | $-455,620,000 |
| Gross Profit | $620,800,000 | $392,700,000 | $140,900,000 | $51,642,000 |
| Special Income Charges | - | $-4,423,000 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.62 | $-0.96 | $-2.94 | $-2.80 |
| Basic EPS | $-1.62 | $-0.96 | $-2.94 | $-2.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $-35,448,000 | $22,953,000 | $-102,999 | $4,515,630 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-63,500,000 | $-224,400,000 | $-451,700,000 | $-438,039,000 |
| Total Unusual Items | $-168,800,000 | $109,300,000 | $-28,200,000 | $21,503,000 |
| Total Unusual Items Excluding Goodwill | $-168,800,000 | $109,300,000 | $-28,200,000 | $21,503,000 |
| Reconciled Depreciation | $28,900,000 | $21,400,000 | $18,500,000 | $18,392,000 |
| EBITDA (Bullshit earnings) | $-232,300,000 | $-115,100,000 | $-479,900,000 | $-416,536,000 |
| EBIT | $-261,200,000 | $-136,500,000 | $-498,400,000 | $-434,928,000 |
| Diluted Average Shares | $184,320,585 | $182,851,072 | $176,082,709 | $159,041,956 |
| Basic Average Shares | $184,320,585 | $182,851,072 | $176,082,709 | $159,041,956 |
| Diluted NI Availto Com Stockholders | $-296,800,000 | $-177,000,000 | $-518,300,000 | $-446,349,000 |
| Tax Provision | $14,200,000 | $18,900,000 | $-1,900,000 | $625,000 |
| Gain On Sale Of Security | $-168,800,000 | $109,300,000 | $-28,200,000 | $21,503,000 |
| Research And Development | $414,700,000 | $413,500,000 | $382,200,000 | $335,648,000 |
| Selling General And Administration | $341,600,000 | $284,300,000 | $201,000,000 | $174,048,000 |
| Other Gand A | $135,800,000 | $136,800,000 | $106,800,000 | $80,631,000 |
| Write Off | - | $4,423,000 | $0 | $0 |
| Impairment Of Capital Assets | - | $4,423,000 | $0 | $0 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $927,500,000 | $866,300,000 | $1,096,094,000 | $675,627,000 |
| Total Assets | $1,733,700,000 | $1,670,200,000 | $1,848,609,000 | $1,330,963,000 |
| Total Non Current Assets | $486,600,000 | $386,300,000 | $350,810,000 | $231,844,000 |
| Non Current Prepaid Assets | $5,000,000 | $5,900,000 | $1,208,000 | $1,092,000 |
| Investmentin Financial Assets | $5,000,000 | $4,400,000 | $4,362,000 | $0 |
| Goodwill And Other Intangible Assets | $74,600,000 | $174,300,000 | $155,277,000 | $68,685,000 |
| Other Intangible Assets | $74,600,000 | $174,300,000 | $155,277,000 | $68,685,000 |
| Current Assets | $1,247,100,000 | $1,283,900,000 | $1,497,799,000 | $1,099,119,000 |
| Other Current Assets | $1,600,000 | - | - | - |
| Prepaid Assets | $14,600,000 | $12,300,000 | $12,231,000 | $17,330,000 |
| Inventory | $32,000,000 | $23,900,000 | $19,433,000 | $10,354,000 |
| Receivables | $250,300,000 | $125,100,000 | $157,061,000 | $44,515,000 |
| Other Receivables | $229,100,000 | $114,100,000 | $56,256,000 | $41,512,000 |
| Taxes Receivable | $8,100,000 | $4,600,000 | $717,000 | $1,396,000 |
| Accounts Receivable | $13,100,000 | $6,400,000 | $100,041,000 | $90,000 |
| Cash Cash Equivalents And Short Term Investments | $948,600,000 | $1,122,600,000 | $1,308,717,000 | $1,025,650,000 |
| Cash And Cash Equivalents | $901,900,000 | $286,700,000 | $1,277,713,000 | $786,031,000 |
| Cash Financial | $901,900,000 | $286,700,000 | - | - |
| Other Non Current Assets | - | $100,000 | $1,493,000 | - |
| Restricted Cash | - | $70,000 | $357,000 | $1,270,000 |
| Accrued Interest Receivable | - | $0 | $47,000 | $1,517,000 |
| Non Current Accounts Receivable | - | - | $285,000 | $395,000 |
| Gross Accounts Receivable | - | - | - | $90,000 |
| Allowance For Doubtful Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $413,700,000 | $350,600,000 | $328,672,000 | $284,534,000 |
| Long Term Debt And Capital Lease Obligation | $87,200,000 | $345,800,000 | $325,497,000 | $280,971,000 |
| Current Debt And Capital Lease Obligation | $326,500,000 | $4,800,000 | $3,175,000 | $3,563,000 |
| Current Debt | $319,100,000 | - | - | - |
| Other Current Borrowings | $319,100,000 | - | - | - |
| Net Debt | - | $14,500,000 | - | - |
| Long Term Debt | - | $301,200,000 | $281,328,000 | $260,932,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $731,600,000 | $629,600,000 | $597,238,000 | $586,651,000 |
| Total Non Current Liabilities Net Minority Interest | $95,200,000 | $351,900,000 | $380,820,000 | $288,863,000 |
| Other Non Current Liabilities | $8,000,000 | $6,100,000 | $56,000 | $233,000 |
| Current Liabilities | $636,400,000 | $277,700,000 | $216,418,000 | $297,788,000 |
| Other Current Liabilities | $1,000,000 | $500,000 | - | $67,000,000 |
| Current Deferred Liabilities | $11,300,000 | $46,900,000 | $53,078,000 | $451,000 |
| Payables And Accrued Expenses | $297,600,000 | $225,500,000 | $160,165,000 | $226,774,000 |
| Payables | $184,300,000 | $166,000,000 | $101,573,000 | $77,492,000 |
| Other Payable | $74,200,000 | $103,300,000 | $61,631,000 | $33,812,000 |
| Total Tax Payable | $27,100,000 | $24,100,000 | $9,287,000 | $10,787,000 |
| Accounts Payable | $81,200,000 | $37,200,000 | $30,055,000 | $31,693,000 |
| Non Current Deferred Liabilities | - | $6,154,000 | $55,267,000 | $7,659,000 |
| Minimum Pension Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,002,100,000 | $1,040,600,000 | $1,251,371,000 | $744,312,000 |
| Total Equity Gross Minority Interest | $1,002,100,000 | $1,040,600,000 | $1,251,371,000 | $744,312,000 |
| Stockholders Equity | $1,002,100,000 | $1,040,600,000 | $1,251,371,000 | $744,312,000 |
| Other Equity Interest | $88,000,000 | $74,400,000 | $54,621,000 | $39,049,000 |
| Gains Losses Not Affecting Retained Earnings | $122,200,000 | $-68,200,000 | $44,304,000 | $14,671,000 |
| Retained Earnings | $-1,958,500,000 | $-1,661,700,000 | $-1,484,710,000 | $-966,456,000 |
| Other Equity Adjustments | - | - | - | $-966,456,000 |
| Other | ||||
| Ordinary Shares Number | $369,886,369 | $367,298,315 | $363,822,069 | $330,134,480 |
| Share Issued | $369,886,369 | $367,298,315 | $363,822,069 | $330,134,480 |
| Tangible Book Value | $927,500,000 | $866,300,000 | $1,096,094,000 | $675,627,000 |
| Invested Capital | $1,321,200,000 | $1,341,800,000 | $1,532,699,000 | $1,005,244,000 |
| Working Capital | $610,700,000 | $1,006,200,000 | $1,281,381,000 | $801,331,000 |
| Capital Lease Obligations | $94,600,000 | $49,400,000 | $47,344,000 | $23,602,000 |
| Total Capitalization | $1,002,100,000 | $1,341,800,000 | $1,532,699,000 | $1,005,244,000 |
| Foreign Currency Translation Adjustments | $122,200,000 | $-68,200,000 | $44,304,000 | $14,671,000 |
| Additional Paid In Capital | $2,750,300,000 | $2,696,000,000 | $2,637,120,000 | $1,657,015,000 |
| Capital Stock | $100,000 | $100,000 | $36,000 | $33,000 |
| Common Stock | $100,000 | $100,000 | $36,000 | $33,000 |
| Long Term Capital Lease Obligation | $87,200,000 | $44,600,000 | $44,169,000 | $20,039,000 |
| Current Deferred Revenue | $11,300,000 | $46,900,000 | $53,078,000 | $451,000 |
| Current Capital Lease Obligation | $7,400,000 | $4,800,000 | $3,175,000 | $3,563,000 |
| Current Accrued Expenses | $113,300,000 | $59,500,000 | $58,592,000 | $149,282,000 |
| Dueto Related Parties Current | $1,800,000 | $1,400,000 | $600,000 | $1,200,000 |
| Investments And Advances | $5,000,000 | $4,400,000 | $4,362,000 | $0 |
| Available For Sale Securities | $5,000,000 | $4,400,000 | $4,362,000 | - |
| Net PPE | $402,000,000 | $201,600,000 | $189,678,000 | $161,672,000 |
| Accumulated Depreciation | $-53,500,000 | $-43,700,000 | $-35,002,000 | $-25,209,000 |
| Gross PPE | $455,500,000 | $245,300,000 | $224,680,000 | $186,881,000 |
| Leases | $22,600,000 | $21,300,000 | $23,117,000 | $21,974,000 |
| Construction In Progress | $14,700,000 | $4,800,000 | $3,490,000 | $15,098,000 |
| Other Properties | $28,700,000 | $24,500,000 | $76,351,000 | $46,346,000 |
| Machinery Furniture Equipment | $64,300,000 | $51,800,000 | $45,480,000 | $46,255,000 |
| Buildings And Improvements | $319,600,000 | $136,300,000 | $69,161,000 | $49,962,000 |
| Land And Improvements | $5,600,000 | $6,600,000 | $7,081,000 | $7,246,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $6,800,000 | $2,000,000 | $3,288,000 | $2,675,000 |
| Work In Process | $1,100,000 | $4,400,000 | $2,990,000 | $690,000 |
| Raw Materials | $24,100,000 | $17,500,000 | $13,155,000 | $6,989,000 |
| Other Short Term Investments | $46,700,000 | $835,900,000 | $31,004,000 | $239,619,000 |
| Non Current Deferred Revenue | - | $6,154,000 | $55,267,000 | $7,659,000 |
| Other Investments | - | - | - | $0 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-128,800,000 | $-158,100,000 | $-416,000,000 | $-223,556,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-100,200,000 | $-144,000,000 | $-393,300,000 | $-201,281,000 |
| Cash Flow From Continuing Operating Activities | $-100,200,000 | $-144,000,000 | $-393,300,000 | $-201,281,000 |
| Operating Gains Losses | $168,800,000 | $-109,300,000 | $114,000,000 | $-11,260,000 |
| Investing Activities | ||||
| Capital Expenditure | $-28,600,000 | $-14,100,000 | $-22,700,000 | $-22,275,000 |
| Investing Cash Flow | $709,600,000 | $-850,600,000 | $92,900,000 | $-77,092,000 |
| Cash Flow From Continuing Investing Activities | $709,600,000 | $-850,600,000 | $92,900,000 | $-77,092,000 |
| Net Other Investing Changes | $-38,800,000 | $-54,400,000 | $-97,900,000 | $-14,705,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $583,700,000 | $377,643,000 |
| Financing Cash Flow | $-300,000 | $5,700,000 | $791,400,000 | $377,976,000 |
| Cash Flow From Continuing Financing Activities | $-300,000 | $5,700,000 | $791,400,000 | $377,976,000 |
| Net Common Stock Issuance | $0 | $0 | $583,700,000 | $377,643,000 |
| Common Stock Issuance | $0 | $0 | $583,700,000 | $377,643,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-3,600,000 | $-4,000,000 | $-3,800,000 | $-2,596,000 |
| End Cash Position | $901,900,000 | $286,700,000 | $1,277,700,000 | $786,031,000 |
| Beginning Cash Position | $286,700,000 | $1,277,700,000 | $786,000,000 | $688,938,000 |
| Effect Of Exchange Rate Changes | $6,100,000 | $-2,100,000 | $700,000 | $-2,510,000 |
| Changes In Cash | $609,100,000 | $-988,900,000 | $491,000,000 | $99,603,000 |
| Proceeds From Stock Option Exercised | $3,300,000 | $9,700,000 | $211,500,000 | $2,929,000 |
| Net Issuance Payments Of Debt | $-3,600,000 | $-4,000,000 | $-3,800,000 | $-2,596,000 |
| Net Long Term Debt Issuance | $-3,600,000 | $-4,000,000 | $-3,800,000 | $-2,596,000 |
| Long Term Debt Payments | $-3,600,000 | $-4,000,000 | $-3,800,000 | $-2,596,000 |
| Net Investment Purchase And Sale | $777,000,000 | $-782,100,000 | $213,500,000 | $-40,112,000 |
| Sale Of Investment | $5,319,900,000 | $1,930,100,000 | $5,076,600,000 | $614,859,000 |
| Purchase Of Investment | $-4,542,900,000 | $-2,712,200,000 | $-4,863,100,000 | $-654,971,000 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-2,600,000 | $-1,348,000 |
| Purchase Of Intangibles | $0 | $0 | $-2,600,000 | $-1,348,000 |
| Net PPE Purchase And Sale | $-28,600,000 | $-14,100,000 | $-20,100,000 | $-20,927,000 |
| Purchase Of PPE | $-28,600,000 | $-14,100,000 | $-20,100,000 | $-20,927,000 |
| Taxes Refund Paid | $-18,400,000 | $-1,600,000 | $300,000 | $3,709,000 |
| Interest Received Cfo | $52,000,000 | $37,300,000 | $47,300,000 | $5,580,000 |
| Change In Working Capital | $-93,100,000 | $18,400,000 | $-72,700,000 | $181,029,000 |
| Change In Other Working Capital | $-36,600,000 | $-54,500,000 | $100,600,000 | $-15,000 |
| Change In Payables And Accrued Expense | $80,500,000 | $58,000,000 | $-52,900,000 | $191,733,000 |
| Change In Payable | $80,500,000 | $58,000,000 | $-52,900,000 | $191,733,000 |
| Change In Account Payable | $44,400,000 | $14,100,000 | $-50,200,000 | $72,446,000 |
| Change In Prepaid Assets | $-126,800,000 | $-61,700,000 | $-8,700,000 | $-50,614,000 |
| Change In Inventory | $-4,500,000 | $-17,200,000 | $-12,700,000 | $-13,893,000 |
| Change In Receivables | $-5,700,000 | $93,800,000 | $-99,000,000 | $50,320,000 |
| Changes In Account Receivables | $-5,700,000 | $93,800,000 | $-99,000,000 | $50,320,000 |
| Other Non Cash Items | $-17,400,000 | $-38,100,000 | $-31,100,000 | $8,487,000 |
| Stock Based Compensation | $64,600,000 | $68,900,000 | $47,700,000 | $34,338,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $-700,000 | $-593,000 |
| Provisionand Write Offof Assets | $-3,000,000 | $12,700,000 | $3,600,000 | $5,288,000 |
| Asset Impairment Charge | $0 | $4,400,000 | $0 | $0 |
| Depreciation Amortization Depletion | $28,900,000 | $21,400,000 | $18,500,000 | $18,392,000 |
| Depreciation And Amortization | $28,900,000 | $21,400,000 | $18,500,000 | $18,392,000 |
| Depreciation | $28,900,000 | $21,400,000 | $18,500,000 | $15,916,000 |
| Net Foreign Currency Exchange Gain Loss | $168,800,000 | $-109,300,000 | $28,200,000 | $9,159,000 |
| Net Income From Continuing Operations | $-282,600,000 | $-158,100,000 | $-520,200,000 | $-445,724,000 |
| Interest Paid Cfo | - | $-1,770,000 | $-1,394,000 | $-527,000 |
| Change In Other Current Liabilities | - | $-55,000 | $-176,000 | $-163,000 |
| Change In Other Current Assets | - | $-4,563,000 | $753,000 | $3,661,000 |
| Amortization Cash Flow | - | $1,931,000 | $1,924,000 | $2,476,000 |
| Amortization Of Intangibles | - | $1,931,000 | $1,924,000 | $2,476,000 |
| Gain Loss On Sale Of PPE | - | $2,000 | $226,000 | $481,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $85,800,000 | $-20,900,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-22